ArticleMedicine2026
Evaluating adverse reaction signals of vancomycin in pediatric patients: A FAERS database analysis.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Based on the US FDA Adverse Event Reporting System, the adverse reaction (AE) signals of vancomycin in pediatric patients were mined, and its safety characteristics and risk association were evaluated. Data from 2004 to 2024 were extracted. The AE reports (n = 20,983) with vancomycin as the primary suspected drug were screened and standardized by MedDRA (version 26.1). Multi-algorithm fusion strategies were used to detect the signal intensity, and the effects of gender, age, and weight on AE distribution were analyzed. Male, 12 to 18 years old, weight ≥45 kg; the US reported the most, and the main outcome was hospitalization. Skin and subcutaneous tissue disorders reported the most, while renal and urinary disorders have the strongest signal. Acute kidney injury is the most common, and linear immunoglobulin A disease has the highest signal intensity. Acute kidney injury is the main factor for both men and women. The <1 year-old-group has the highest risk of renal and urinary disorders. The signal of renal and urinary disorders was significant in the group <10 kg. Vancomycin is related to nephrotoxicity, skin reaction, and rare immune diseases in pediatric patients, especially in low-birth-weight infants and adolescents. Strengthening therapeutic drug monitoring and individualized medication strategies and paying attention to the influence of gender and geographical differences on AE reports is necessary. This study provides data support for optimizing the safety management of vancomycin in children; however, prospective research is necessary to verify the clinical significance of the FDA Adverse Event Reporting System signal.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.